ViralClear closed $10.8 million equity financing for development of COVID-19 broad-spectrum oral anti-viral candidate merimepodib
On May 20, 2020, BioSig Technologies and its subsidiary, ViralClear Pharmaceuticals, announced the closing of a $10.8 million…